

## **Svelte™ Medical Systems, Inc. Receives CE Mark Approval to Market the Svelte *Acrobat* Stent-on-a-Wire (SOAW) Coronary Stent System**

**New Providence, NJ, August 23, 2010**—Svelte™ Medical Systems, Inc. is pleased to announce that it has officially received the CE Mark to market its *Acrobat* Stent-on-a-Wire (SOAW) Bare Metal Coronary Stent System in the European Union. The *Acrobat* SOAW stenting system has been shown in clinical trials to facilitate direct stenting and has the potential to provide substantial procedural time and cost savings. These savings are realized by eliminating the need for a coronary guidewire and balloon dilatation catheters. Furthermore, the *Acrobat* stent allows reduced use of contrast medium which is a benefit to many patients. Another important advantage when using the *Acrobat* stenting system is that the operator and patient radiation dosing is significantly reduced. The extremely low crossing profile of the *Acrobat* stent makes it well suited for stenting via the radial artery approach which provides additional comfort and safety benefits to the patient.

Svelte's President and CEO, Mark Pomeranz has stated that "This is obviously a most significant milestone for the Company. We successfully concluded our First-In-Man (FIM) clinical evaluations at the end of July and with receipt of the CE Mark we will be able to make this exciting product commercially available to a broad range of physicians and patients. Distribution of the *Acrobat* stent within the EU and Brazil will commence in September. We feel confident that the market will respond positively and that the *Acrobat* will gain a significant share of the market for coronary stents."

The Company plans to initiate U.S. clinical trials on the *Acrobat* SOAW technology in 2011. A drug eluting version of the *Acrobat* stent is now under development using a novel non-inflammatory carrier for the drug.

To enhance the familiarity with the *Acrobat* stent product for physicians, Svelte Medical Systems will be exhibiting at the European Society of Cardiology (ESC) Congress in Stockholm, Sweden August 28 – September 1<sup>st</sup>. Additional details about Svelte's products are available at [www.sveltemedical.com](http://www.sveltemedical.com).

Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes or benefits are forward-looking statements. A number of risks and uncertainties such as risks associated with product development and commercialization efforts, results of clinical trials, ultimate clinical outcomes and benefit of the Company's products to patients, market and physician acceptance of the products, intellectual property protection and competitive product offerings could cause actual events to adversely differ from the expectations indicated in these forward looking statements.

For additional information please contact: Mark Pomeranz , Svelte President/CEO, at [mpomeranz@sveltemedical.com](mailto:mpomeranz@sveltemedical.com) , or phone: 908-264-2195